Breast cancer: current developments in molecular approaches to diagnosis and treatment
- PMID: 24171821
- DOI: 10.2174/15748928113086660046
Breast cancer: current developments in molecular approaches to diagnosis and treatment
Abstract
Due to the high heterogeneity of breast cancers, numerous recent patents describe improved methods of detection and classification which promise better patient prognosis and treatment. In particular, there has been a shift towards more effective genetic screening to identify specific mutations associated with breast tumours, which may lead to "personalised medicine" with improved outcomes. Two challenging areas of breast cancer research involve the development of treatments for the highly aggressive triple negative breast cancer subtype as well as the chemotherapy-resistant cancer stem cell subpopulation. In addition, despite numerous recent advances in breast cancer treatment in woman, male breast cancer remains poorly understood and there are limited therapies available which are developed specifically for men. This review serves to report on important developments in the treatment of breast malignancies patented in the past two years as well as to highlight the current gaps in the field of breast cancer therapeutics and areas which require further study.
Similar articles
-
Proteomics as a Guide for Personalized Adjuvant Chemotherapy in Patients with Early Breast Cancer.Cancer Genomics Proteomics. 2015 Nov-Dec;12(6):385-90. Cancer Genomics Proteomics. 2015. PMID: 26543084 Review.
-
Advances in chemical pharmacotherapy to manage advanced breast cancer.Expert Opin Pharmacother. 2017 Jan;18(1):95-103. doi: 10.1080/14656566.2016.1269748. Epub 2016 Dec 16. Expert Opin Pharmacother. 2017. PMID: 27927046 Review.
-
Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.Curr Oncol Rep. 2018 Aug 20;20(10):76. doi: 10.1007/s11912-018-0726-6. Curr Oncol Rep. 2018. PMID: 30128845
-
Emerging Therapeutic Strategies in Breast Cancer.South Med J. 2017 Oct;110(10):632-637. doi: 10.14423/SMJ.0000000000000709. South Med J. 2017. PMID: 28973703 Review.
-
Checkpoint inhibitors in breast cancer: hype or promise?Clin Adv Hematol Oncol. 2016 Jun;14(6):392-5. Clin Adv Hematol Oncol. 2016. PMID: 27379806 No abstract available.
Cited by
-
Role of PAX2 in breast cancer verified by bioinformatics analysis and in vitro validation.Ann Transl Med. 2023 Jan 31;11(2):58. doi: 10.21037/atm-22-6360. Ann Transl Med. 2023. PMID: 36819548 Free PMC article.
-
Triptolide induces autophagy and apoptosis through ERK activation in human breast cancer MCF-7 cells.Exp Ther Med. 2018 Apr;15(4):3413-3419. doi: 10.3892/etm.2018.5830. Epub 2018 Feb 1. Exp Ther Med. 2018. PMID: 29545863 Free PMC article.
-
MicroRNA-374c-5p inhibits the development of breast cancer through TATA-box binding protein associated factor 7-mediated transcriptional regulation of DEP domain containing 1.J Cell Biochem. 2019 Sep;120(9):15360-15368. doi: 10.1002/jcb.28803. Epub 2019 Jun 4. J Cell Biochem. 2019. PMID: 31162714 Free PMC article.
-
Role of microRNA-150-5p/SRCIN1 axis in the progression of breast cancer.Exp Ther Med. 2019 Mar;17(3):2221-2229. doi: 10.3892/etm.2019.7206. Epub 2019 Jan 28. Exp Ther Med. 2019. PMID: 30867707 Free PMC article.
-
The serum protein profile of early parity which induces protection against breast cancer.Oncotarget. 2016 Dec 13;7(50):82538-82553. doi: 10.18632/oncotarget.12757. Oncotarget. 2016. PMID: 27769065 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous